Little Known Facts About AZD0156.
Kantarjian et al53 assessed the efficacy and basic safety of dasatinib, as when compared with imatinib, for the initial-line remedy of CML-CP. 5 hundred and nineteen sufferers with newly diagnosed CML-CP ended up randomly assigned to receive dasatinib at a dose of 100 mg the moment each day (259 sufferers) or imatinib at a dose of four hundred mg w